Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zai Lab Limited

< Previous 1 2 Next >
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Participation in March Investor Conference
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Participation in January Investor Conference
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Participation in November Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Participation in September Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From Zai Lab Limited
Via GlobeNewswire
Tickers ARGX ZLAB
Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via GlobeNewswire
Tickers ARGX ZLAB
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
From Zai Lab Limited
Via GlobeNewswire
Tickers NVCR ZLAB
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Participation in June Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zai Lab Limited
Via GlobeNewswire
Tickers ZLAB
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.